Fungi in Bronchiectasis: A Concise Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Jan 5

PMID 29300314

Citations 23

Authors

Luis Maiz

Rosa Nieto

Rafael Canton

Elia Gomez G de la Pedrosa

Miguel Angel Martinez-Garcia

Affiliations

Soon will be listed here.

Abstract

Although the spectrum of fungal pathology has been studied extensively in immunosuppressed patients, little is known about the epidemiology, risk factors, and management of fungal infections in chronic pulmonary diseases like bronchiectasis. In bronchiectasis patients, deteriorated mucociliary clearance-generally due to prior colonization by bacterial pathogens-and thick mucosity propitiate, the persistence of fungal spores in the respiratory tract. The most prevalent fungi in these patients are and ; these are almost always isolated with bacterial pathogens like and , making very difficult to define their clinical significance. Analysis of the mycobiome enables us to detect a greater diversity of microorganisms than with conventional cultures. The results have shown a reduced fungal diversity in most chronic respiratory diseases, and that this finding correlates with poorer lung function. Increased knowledge of both the mycobiome and the complex interactions between the fungal, viral, and bacterial microbiota, including mycobacteria, will further our understanding of the mycobiome's relationship with the pathogeny of bronchiectasis and the development of innovative therapies to combat it.

Citing Articles

Pulmonary microbiology and microbiota in adults with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.

Wang Y, Xiao J, Yang X, Liu Y, Du J, Bossios A Respir Res. 2025; 26(1):77.

PMID: 40022075 PMC: 11871666. DOI: 10.1186/s12931-025-03140-w.

Fungal lung disease.

Jaggi T, Agarwal R, Tiew P, Shah A, Lydon E, Hage C Eur Respir J. 2024; 64(5).

PMID: 39362667 PMC: 11602666. DOI: 10.1183/13993003.00803-2024.

Infection and the microbiome in bronchiectasis.

Mac Aogain M, Dicker A, Mertsch P, Chotirmall S Eur Respir Rev. 2024; 33(173).

PMID: 38960615 PMC: 11220623. DOI: 10.1183/16000617.0038-2024.

Should atelectasis be considered a pulmonary complication and indicator of poor prognosis in cystic fibrosis?.

Martinez Redondo M, Segura C, Zamarron de Lucas E, Alvarez-Sala Walther R, Prados Sanchez C J Int Med Res. 2024; 52(3):3000605241233520.

PMID: 38546237 PMC: 10981250. DOI: 10.1177/03000605241233520.

Multicentric Study on the Clinical Mycology Capacity and Access to Antifungal Treatment in Portugal.

Fernandes R, Sabino R, Cunha C, Cornely O, Carvalho A, Salmanton-Garcia J Mycopathologia. 2024; 189(1):15.

PMID: 38265528 PMC: 10808446. DOI: 10.1007/s11046-024-00830-9.

References

Maiz L, Cuevas M, Lamas A, Sousa A, Quirce S, Suarez L . [Aspergillus fumigatus and Candida albicans in cystic fibrosis: clinical significance and specific immune response involving serum immunoglobulins G, A, and M]. Arch Bronconeumol. 2008; 44(3):146-51. DOI: 10.1016/s1579-2129(08)60029-4. View

Namvar S, Warn P, Farnell E, Bromley M, Fraczek M, Bowyer P . Aspergillus fumigatus proteases, Asp f 5 and Asp f 13, are essential for airway inflammation and remodelling in a murine inhalation model. Clin Exp Allergy. 2014; 45(5):982-993. DOI: 10.1111/cea.12426. View

Viviani L, Harrison M, Zolin A, Haworth C, Floto R . Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF). J Cyst Fibros. 2016; 15(5):619-23. DOI: 10.1016/j.jcf.2016.03.002. View

Underhill D, Iliev I . The mycobiota: interactions between commensal fungi and the host immune system. Nat Rev Immunol. 2014; 14(6):405-16. PMC: 4332855. DOI: 10.1038/nri3684. View

Chotirmall S, ODonoghue E, Bennett K, Gunaratnam C, ONeill S, McElvaney N . Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis. Chest. 2010; 138(5):1186-95. DOI: 10.1378/chest.09-2996. View

Bargon J, Dauletbaev N, Kohler B, Wolf M, Posselt H, Wagner T . Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med. 1999; 93(11):835-8. DOI: 10.1016/s0954-6111(99)90270-6. View

Kosmidis C, Denning D . The clinical spectrum of pulmonary aspergillosis. Thorax. 2014; 70(3):270-7. DOI: 10.1136/thoraxjnl-2014-206291. View

Martinez-Garcia M, Maiz L, Olveira C, Giron R, de la Rosa D, Blanco M . Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults. Arch Bronconeumol (Engl Ed). 2017; 54(2):79-87. DOI: 10.1016/j.arbres.2017.07.015. View

King P, Holdsworth S, Freezer N, Villanueva E, Holmes P . Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007; 101(8):1633-8. DOI: 10.1016/j.rmed.2007.03.009. View

10.

Jubin V, Ranque S, Stremler le Bel N, Sarles J, Dubus J . Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol. 2010; 45(8):764-71. DOI: 10.1002/ppul.21240. View

11.

Kraemer R, Delosea N, Ballinari P, Gallati S, Crameri R . Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med. 2006; 174(11):1211-20. DOI: 10.1164/rccm.200603-423OC. View

12.

Angrill J, Agusti C, De Celis R, Rano A, Gonzalez J, Sole T . Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002; 57(1):15-9. PMC: 1746176. DOI: 10.1136/thorax.57.1.15. View

13.

Mussaffi H, Rivlin J, Shalit I, Ephros M, Blau H . Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J. 2005; 25(2):324-8. DOI: 10.1183/09031936.05.00058604. View

14.

Kurup V . Interaction of Aspergillus fumigatus spores and pulmonary alveolar macrophages of rabbits. Immunobiology. 1984; 166(1):53-61. DOI: 10.1016/S0171-2985(84)80143-6. View

15.

Levy I, Grisaru-Soen G, Lerner-Geva L, Kerem E, Blau H, Bentur L . Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis. 2008; 14(3):378-84. PMC: 2570835. DOI: 10.3201/eid1403.061405. View

16.

Levitz S, Selsted M, Ganz T, Lehrer R, DIAMOND R . In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis. 1986; 154(3):483-9. DOI: 10.1093/infdis/154.3.483. View

17.

COLE P . Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl. 1986; 147:6-15. View

18.

Tillie-Leblond I, Tonnel A . Allergic bronchopulmonary aspergillosis. Allergy. 2005; 60(8):1004-13. DOI: 10.1111/j.1398-9995.2005.00887.x. View

19.

Aliberti S, Masefield S, Polverino E, Soyza A, Loebinger M, Menendez R . Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J. 2016; 48(3):632-47. DOI: 10.1183/13993003.01888-2015. View

20.

Ishiguro T, Takayanagi N, Kagiyama N, Shimizu Y, Yanagisawa T, Sugita Y . Clinical characteristics of biopsy-proven allergic bronchopulmonary mycosis: variety in causative fungi and laboratory findings. Intern Med. 2014; 53(13):1407-11. DOI: 10.2169/internalmedicine.53.2230. View